WU-SN-TMC Biospecimen Core

生物样本核心摘要/摘要 衰老是一个复杂的表型，可能包括许多状态，这些状态与人类的衰老有关。 健康和疾病。我们的目标是建立华盛顿大学衰老组织绘图中心（WU- SN-TMC），它将利用我们庞大的基础设施来生成多组学和成像数据， 高分辨率、多维的组织类型和寿命的细胞衰老图谱， 用于支持基础和转化衰老研究。我们的WU-SN-TMC将开发蜂窝 衰老图谱使用500个人类样本的四种基本组织类型：骨髓，乳腺，结肠， 和肝脏。为了实现这一雄心勃勃的目标，WU-SN-TMC生物标本核心（WU-SN-TMC BC）已被 旨在方便收集不同年龄段的人体组织。此外，WU-SN- TMC BC将从个体中收集多个组织，以便我们比较衰老的数量和状态 从一个人的组织中分离出来WU-SN-TMC BC将通过使用样品 采集管道分为四个组织前瞻性采集协议（CP）， 临床专业知识和患者数量，以收集相关生物标本。这些CP包括：1）CP 1，它将 收集来自不同年龄的无慢性疾病的正常供体的骨髓; 2）CP 2，其包括正常 来自不同年龄接受乳房美容手术的患者的乳房、骨髓和皮肤; 3）CP 3， 包括接受内窥镜检查的患者，他们将提供正常的胃、小肠和结肠， 年龄;和4）CP 4包括接受腹腔镜上消化道手术的患者， 骨髓、肝脏和皮肤都正常。虽然我们的重点是在人类衰老过程中 由于年龄的增长，CP 2和CP 4中的一些患者将接受先前的非相关组织癌症化疗 (i.e.生物样本将来自未受影响的、无癌组织）。这一群体将提供机会， 比较年龄匹配的对照+/-化疗，并允许在小鼠中进行生物学试验 分析核心（BAC）将被映射回人体组织的相关性，进一步丰富骨髓， 我们将制作乳腺、结肠和肝脏图谱。WU的现有基础设施，我们的患者数量和 我们团队的专业知识将确保WU-SN-TMC BC的成功。

Biospecimen Core Summary/Abstract Senescence is a complex phenotype that likely consists of many states that have been implicated in human health and disease. We aim to create the Washington University Senescence Tissue Mapping Center (WU- SN-TMC), which will leverage our expansive infrastructure to generate multi-omics and imaging data to build high resolution, multi-dimensional atlases of cellular senescence across tissue types and lifespan that can be used to enable basic and translational senescence research. Our WU-SN-TMC will develop cellular senescence atlases using 500 human samples for four essential tissue types: bone marrow, breast, colon, and liver. To tackle such an ambitious goal, the WU-SN-TMC Biospecimen Core (WU-SN-TMC BC) has been designed to facilitate the collection of human tissues across a wide range of ages. In addition, the WU-SN- TMC BC will collect multiple tissues from individuals to allow us to compare senescent numbers and states across tissues from a single individual. The WU-SN-TMC BC will accomplish this goal by using sample acquisition pipelines that are divided into four tissue prospective collection protocols (CPs) that leverage WU clinical expertise and patient volume to collect relevant biospecimens. These CPs include: 1) CP1, which will collect bone marrow from normal donors without chronic disease across ages; 2) CP2, which includes normal breast, bone marrow and skin from patients undergoing cosmetic breast surgery across ages; 3) CP3, which includes patients undergoing endoscopy who will provide normal stomach, small bowel, and colon across ages; and 4) CP4 includes patients undergoing laparoscopic upper gastrointestinal surgery that will provide normal bone marrow, liver, and skin, again across ages. While our focus is on senescence during human aging, some patients in CP2 and CP4 will have received prior chemotherapy for cancers in unrelated tissues (i.e. biospecimens will be from unaffected, cancer-free tissues). This cohort will provide the opportunity to compare age-matched controls +/- chemotherapy and allow perturbations tested in mice in the Biological Analysis Core (BAC) to be mapped back to human tissue for relevance, further enriching the bone marrow, breast, colon, and liver atlases we will produce. The existing infrastructure at WU, our patient volume and the expertise of our team will ensure the success of the WU-SN-TMC BC.